Acquired Company
Emergex Vaccines Holding Limited acquired Zosano Pharma's operating assets on October 12, 2022, including the microneedle patch technology and manufacturing equipment, with ownership of Zosano's NDA subsequently transferred to Emergex in May 2023.
Zosano Pharma Corporation is a clinical-stage biopharmaceutical company focused on developing products where rapid administration of approved molecules with established safety and efficacy profiles may provide substantial benefit to patients, in markets where patients remain underserved by existing therapies. The company's transdermal microneedle system technology consists of titanium microneedles coated with drug that are designed to enable rapid systemic administration of therapeutics to patients. Zosano's lead product candidate is Qtrypta™ (M207), which is a proprietary formulation of zolmitriptan designed to be delivered via its transdermal microneedle system technology, as an acute treatment for migraine. Show more
Location: 34790 Ardentech Ct, California, 94555-3657, US | Website: www.zosanopharma.com | Industry: | Sector:
Market Cap
901.4M
52 Wk Range
$N/A - $N/A
Previous Close
$0.00
Open
$0.00
Volume
5,685
Day Range
$0.00 - $0.00
Enterprise Value
0.00
Cash
159.3M
Avg Qtr Burn
N/A
Insider Ownership
0.00%
Institutional Own.
0.00%
Qtr Updated
03/31/25
Only showing assets and stage. See catalyst data with a free or premium account. Unlock more data with a free account.
| Drug & Indication | Stage & Event | Catalyst Date |
|---|
